Discovering a new nutraceutical based on pollen extract and teupolioside: a prospective monocentric study evaluating its role in alleviating lower urinary tract symptoms in benign prostatic hyperplasia patients.

Background: Benign prostatic hyperplasia (BPH) is a common condition in men over 50, leading to lower urinary tract symptoms (LUTS). A nutraceutical containing pollen extract (Graminex® G96®) and teupolioside has shown potential in alleviating LUTS by targeting inflammation and dihydrotestosterone production. This prospective, monocentric study enrolled 60 patients with mild to moderate LUTS due to BPH.

Methods: Participants received one tablet daily for three months. Assessments included the international prostate symptom score (IPSS), quality of life (QoL), uroflowmetry, postvoid residual (PVR), and sexual function (IIEF-5, MSHQ EjD).

Results: Fifty-three patients completed the follow-up. Significant improvements were observed in IPSS and QoL (p<0.001), with scores decreasing from 14 (11-16) at baseline to 10 (8-12) at three months and decreasing from 3 (2-3) to 2 (2-2), respectively. Uroflowmetry parameters (Qmax and PVR) improved, increasing from 12 (11-16) ml/s to 15 (11-17) ml/s and decreasing from 50 (30-55) ml to 35 (25-45) ml, respectively, without statistical significance (p>0.05). Sexual function and PSA levels remained stable, with no significant adverse effects reported.

Conclusions: The combination of pollen extract and teupolioside effectively alleviates LUTS in BPH patients with a favorable safety profile, particularly in avoiding sexual dysfunction.